| Secondary |
| Diffuse Large B-cell Lymphoma |
20.4% |
| Acute Lymphocytic Leukaemia |
15.4% |
| Lymphoma |
8.2% |
| B-cell Lymphoma |
7.2% |
| Neuroblastoma |
5.2% |
| Langerhans' Cell Granulomatosis |
4.9% |
| Ascites |
4.4% |
| Hepatoblastoma |
4.4% |
| Metastases To Lung |
4.4% |
| Rhabdoid Tumour |
4.4% |
| Lymphoproliferative Disorder |
3.6% |
| Prophylaxis |
3.1% |
| Rhabdomyosarcoma |
2.9% |
| Mantle Cell Lymphoma Stage Iii |
2.5% |
| Acute Myeloid Leukaemia |
1.6% |
| Bone Sarcoma |
1.6% |
| Breast Cancer |
1.6% |
| Drug Use For Unknown Indication |
1.5% |
| Peripheral T-cell Lymphoma Unspecified |
1.5% |
| Mantle Cell Lymphoma |
1.1% |
|
| Hepatic Function Abnormal |
10.9% |
| Reversible Posterior Leukoencephalopathy Syndrome |
10.9% |
| Acute Myeloid Leukaemia |
5.5% |
| Hepatitis B |
5.5% |
| Ileus Paralytic |
5.5% |
| Leukaemia |
5.5% |
| Pyrexia |
5.5% |
| Renal Tubular Disorder |
5.5% |
| White Blood Cell Count Decreased |
5.5% |
| Acute Myelomonocytic Leukaemia |
3.6% |
| Blood Immunoglobulin G Decreased |
3.6% |
| Cystitis Haemorrhagic |
3.6% |
| Epilepsy |
3.6% |
| Febrile Neutropenia |
3.6% |
| Histiocytosis Haematophagic |
3.6% |
| Intestinal Perforation |
3.6% |
| Metastases To Central Nervous System |
3.6% |
| Neoplasm |
3.6% |
| Oral Mucosa Erosion |
3.6% |
| Pancreatic Carcinoma |
3.6% |
|
| Concomitant |
| Diffuse Large B-cell Lymphoma |
23.3% |
| Acute Lymphocytic Leukaemia |
12.2% |
| Lymphoma |
9.4% |
| Drug Use For Unknown Indication |
9.1% |
| B Precursor Type Acute Leukaemia |
6.6% |
| Product Used For Unknown Indication |
5.6% |
| Ewing's Sarcoma |
4.3% |
| Hypertension |
4.1% |
| Central Nervous System Lymphoma |
3.5% |
| Infection Prophylaxis |
3.0% |
| Rhabdomyosarcoma |
2.8% |
| Constipation |
2.0% |
| Infection |
2.0% |
| Mantle Cell Lymphoma |
2.0% |
| Neuroblastoma |
2.0% |
| Neuropathy Peripheral |
2.0% |
| Follicle Centre Lymphoma, Follicular Grade I, Ii, Iii Stage Iv |
1.8% |
| Premedication |
1.8% |
| Malignant Neoplasm Of Pleura |
1.3% |
| Precursor B-lymphoblastic Lymphoma |
1.3% |
|
| White Blood Cell Count Decreased |
12.5% |
| Pleural Effusion |
8.3% |
| Bone Marrow Failure |
6.3% |
| Drug Interaction |
6.3% |
| Pneumocystis Jiroveci Pneumonia |
6.3% |
| Renal Impairment |
6.3% |
| Acute Respiratory Distress Syndrome |
4.2% |
| Fungal Infection |
4.2% |
| Hepatic Function Abnormal |
4.2% |
| Infusion Related Reaction |
4.2% |
| Lung Infection |
4.2% |
| Mucosal Inflammation |
4.2% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
4.2% |
| Pyrexia |
4.2% |
| Respiratory Failure |
4.2% |
| Temporal Lobe Epilepsy |
4.2% |
| Tonsillitis |
4.2% |
| Venoocclusive Liver Disease |
4.2% |
| Acute Lymphocytic Leukaemia |
2.1% |
| Acute Myeloid Leukaemia |
2.1% |
|
